Inhibrx Biosciences (INBX) Competitors $25.00 +0.84 (+3.48%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$24.96 -0.05 (-0.18%) As of 08/22/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. CALT, PAHC, NTLA, AMPH, XERS, COLL, SNDX, PHVS, VERV, and LENZShould you be buying Inhibrx Biosciences stock or one of its competitors? The main competitors of Inhibrx Biosciences include Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), Xeris Biopharma (XERS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Pharvaris (PHVS), Verve Therapeutics (VERV), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Inhibrx Biosciences vs. Its Competitors Calliditas Therapeutics AB (publ) Phibro Animal Health Intellia Therapeutics Amphastar Pharmaceuticals Xeris Biopharma Collegium Pharmaceutical Syndax Pharmaceuticals Pharvaris Verve Therapeutics LENZ Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Does the media favor CALT or INBX? In the previous week, Inhibrx Biosciences had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Inhibrx Biosciences and 0 mentions for Calliditas Therapeutics AB (publ). Inhibrx Biosciences' average media sentiment score of 0.59 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Inhibrx Biosciences Positive Is CALT or INBX more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Inhibrx Biosciences' return on equity of -137.83% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Inhibrx Biosciences N/A -137.83%-76.31% Which has preferable valuation and earnings, CALT or INBX? Inhibrx Biosciences has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Inhibrx Biosciences$1.40M258.66$1.69B-$10.58-2.36 Do analysts rate CALT or INBX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders believe in CALT or INBX? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, CALT or INBX? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. SummaryInhibrx Biosciences beats Calliditas Therapeutics AB (publ) on 10 of the 14 factors compared between the two stocks. Get Inhibrx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$349.96M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-2.3621.2831.3026.05Price / Sales258.66345.81432.98193.75Price / Cash0.2143.1937.7358.48Price / Book5.298.129.536.61Net Income$1.69B-$54.72M$3.26B$265.65M7 Day Performance7.16%2.62%2.13%2.02%1 Month Performance7.76%2.68%2.80%-0.31%1 Year Performance87.41%10.93%30.68%19.06% Inhibrx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx Biosciences1.6699 of 5 stars$25.00+3.5%N/A+92.5%$349.96M$1.40M-2.36166Analyst ForecastShort Interest ↓High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health3.459 of 5 stars$28.54+1.6%$24.40-14.5%+70.8%$1.14B$1.02B36.591,940News CoverageUpcoming EarningsAnalyst RevisionNTLAIntellia Therapeutics4.6197 of 5 stars$10.74-0.5%$30.68+185.7%-54.3%$1.12B$57.88M-2.29600Insider TradeAMPHAmphastar Pharmaceuticals3.4369 of 5 stars$27.36+14.9%$30.00+9.6%-35.4%$1.11B$731.97M10.252,028High Trading VolumeXERSXeris Biopharma3.4404 of 5 stars$7.20+5.3%$6.25-13.2%+176.8%$1.10B$203.07M-34.28290News CoveragePositive NewsAnalyst ForecastAnalyst RevisionCOLLCollegium Pharmaceutical2.1621 of 5 stars$36.14+3.5%$42.33+17.1%+8.5%$1.10B$631.45M34.75210News CoverageInsider TradeSNDXSyndax Pharmaceuticals4.0799 of 5 stars$12.51+0.2%$36.91+195.0%-20.1%$1.08B$23.68M-3.22110PHVSPharvaris2.6317 of 5 stars$20.84+3.6%$36.20+73.7%+27.0%$1.05BN/A-6.9230VERVVerve Therapeutics2.9778 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics1.2589 of 5 stars$38.77+11.8%$49.60+27.9%+80.0%$989.15MN/A-20.41110Gap UpHigh Trading Volume Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Intellia Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Xeris Biopharma Alternatives Collegium Pharmaceutical Alternatives Syndax Pharmaceuticals Alternatives Pharvaris Alternatives Verve Therapeutics Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access